Jianfeng Group: Subsidiary Obtains Compound Tropicamide Eye Drops "Drug Registration Certificate"

The Group announced that its wholly-owned subsidiary Pharmaceutical recently received a Drug Registration Certificate for the compound tropicamide eye drop from the National Medical Products Administration. As of the end of July 2026, the research and development investment for this project is approximately 5.8969 million yuan. The sales revenue of this drug in the domestic market for 2025 is estimated to be around 108 million yuan. This certification signifies that Pharmaceutical is qualified to produce and sell the product, which will help enrich its product line. However, drug production and sales are subject to industry policies, market conditions, and other factors, introducing uncertainties.